COSENTYX 150 MG / 1 ML 1 PRE-FILLED PEN كوزنتكس 150 مجم / 1 مل

EGP4,791.00

مقارنه

** Cosentyx®& (secukinumab 150 mg/mL) Solution for injection in a single-use pre-filled SensoReady® pen. 1 pre-filled pen 150 mg. For subcutaneous use only.

** Composition:
1 pre-filled pen = 150 mg secukinumab

** Therapeutic indications:
– Plaque psoriasis
Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
– Psoriatic arthritis
Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.
– Ankylosing spondylitis
Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.

** Pharmacotherapeutic group:
Immunosuppressants, interleukin inhibitors, ATC code: L04AC10

** Mechanism of action:
Secukinumab is a fully human IgG1/k monoclonal antibody that selectively binds to and neutralises the proinflammatory cytokine interleukin-17A (IL-17A). Secukinumab works by targeting IL-17A and inhibiting its interaction with the IL-17 receptor, which is expressed on various cell types including keratinocytes. As a result, secukinumab inhibits the release of proinflammatory cytokines, chemokines and mediators of tissue damage and reduces IL-17A-mediated contributions to autoimmune and inflammatory diseases. Clinically relevant levels of secukinumab reach the skin and reduce local inflammatory markers. As a direct consequence treatment with secukinumab reduces erythema, induration and desquamation present in plaque psoriasis lesions.
IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. IL-17A plays a key role in the pathogenesis of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis and is up-regulated in lesional skin in contrast to non-lesional skin of plaque psoriasis patients and in synovial tissue of psoriatic arthritis patients. The frequency of IL-17-producing cells was also significantly higher in the subchondral bone marrow of facet joints from patients with ankylosing spondylitis.

** Medicinal product subject to medical prescription.

** Store at 2-8 degrees C (in a refrigerator). Do not freeze.
Store in the original package. Protect from light.
Keep out of the reach and sight of children.

المراجعات

لا توجد مراجعات بعد.

كن أول من يقيم “COSENTYX 150 MG / 1 ML 1 PRE-FILLED PEN كوزنتكس 150 مجم / 1 مل”

لن يتم نشر عنوان بريدك الإلكتروني. الحقول الإلزامية مشار إليها بـ *

Open chat
طلب مساعده ؟
شكرًا على التواصل مع لوميكسا ارسل: 1-العمر,النوع, الوزن 2- الامراض المزمنه